Abcellera Biologics Net Income
| ABCL Stock | USD 3.16 0.03 0.96% |
As of the 19th of February, Abcellera Biologics shows the risk adjusted performance of (0.03), and Mean Deviation of 3.32. Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Abcellera Biologics information ratio, and the relationship between the coefficient of variation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 3.16 per share. Given that Abcellera Biologics has information ratio of (0.06), we suggest you to validate Abcellera Biologics's prevailing market performance to make sure the company can sustain itself at a future point.
Abcellera Biologics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 16.3476 | Revenue | Earnings Share (0.57) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -146.6 M | -139.2 M | |
| Net Income Applicable To Common Shares | 182.3 M | 94.4 M | |
| Net Loss | -146.6 M | -139.2 M | |
| Net Loss | (0.64) | (0.60) | |
| Net Income Per E B T | 0.73 | 0.60 |
Abcellera | Net Income | Build AI portfolio with Abcellera Stock |
Historical Net Income data for Abcellera Biologics serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Abcellera Biologics represents a compelling investment opportunity.
Latest Abcellera Biologics' Net Income Growth Pattern
Below is the plot of the Net Income of Abcellera Biologics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Abcellera Biologics financial statement analysis. It represents the amount of money remaining after all of Abcellera Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Abcellera Biologics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abcellera Biologics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (162.86 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Abcellera Net Income Regression Statistics
| Arithmetic Mean | (18,780,749) | |
| Geometric Mean | 3,412,038 | |
| Coefficient Of Variation | (465.16) | |
| Mean Deviation | 61,170,122 | |
| Median | 309,000 | |
| Standard Deviation | 87,360,847 | |
| Sample Variance | 7631.9T | |
| Range | 321.4M | |
| R-Value | (0.42) | |
| Mean Square Error | 6672.9T | |
| R-Squared | 0.18 | |
| Significance | 0.09 | |
| Slope | (7,345,902) | |
| Total Sum of Squares | 122110.7T |
Abcellera Net Income History
Other Fundumenentals of Abcellera Biologics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Abcellera Biologics Net Income component correlations
Abcellera Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Abcellera Biologics is extremely important. It helps to project a fair market value of Abcellera Stock properly, considering its historical fundamentals such as Net Income. Since Abcellera Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Abcellera Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Abcellera Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Abcellera Biologics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Abcellera Biologics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Abcellera Biologics.
| 11/21/2025 |
| 02/19/2026 |
If you would invest 0.00 in Abcellera Biologics on November 21, 2025 and sell it all today you would earn a total of 0.00 from holding Abcellera Biologics or generate 0.0% return on investment in Abcellera Biologics over 90 days. Abcellera Biologics is related to or competes with Celldex Therapeutics, Vera Therapeutics, Janux Therapeutics, Spyre Therapeutics, Biohaven Pharmaceutical, Sionna Therapeutics, and Immunome. AbCellera Biologics Inc. develops antibody discovery platform More
Abcellera Biologics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Abcellera Biologics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Abcellera Biologics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 28.69 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 6.33 |
Abcellera Biologics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Abcellera Biologics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Abcellera Biologics' standard deviation. In reality, there are many statistical measures that can use Abcellera Biologics historical prices to predict the future Abcellera Biologics' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.08) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Abcellera Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Abcellera Biologics February 19, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.07) | |||
| Mean Deviation | 3.32 | |||
| Coefficient Of Variation | (1,853) | |||
| Standard Deviation | 4.67 | |||
| Variance | 21.81 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.38) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.08) | |||
| Maximum Drawdown | 28.69 | |||
| Value At Risk | (7.10) | |||
| Potential Upside | 6.33 | |||
| Skewness | 0.2081 | |||
| Kurtosis | 2.33 |
Abcellera Biologics Backtested Returns
Abcellera Biologics secures Sharpe Ratio (or Efficiency) of -0.015, which signifies that the company had a -0.015 % return per unit of standard deviation over the last 3 months. Abcellera Biologics exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Abcellera Biologics' risk adjusted performance of (0.03), and Mean Deviation of 3.32 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.12, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Abcellera Biologics will likely underperform. At this point, Abcellera Biologics has a negative expected return of -0.0701%. Please make sure to confirm Abcellera Biologics' coefficient of variation, value at risk, rate of daily change, as well as the relationship between the total risk alpha and kurtosis , to decide if Abcellera Biologics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Abcellera Biologics has poor predictability. Overlapping area represents the amount of predictability between Abcellera Biologics time series from 21st of November 2025 to 5th of January 2026 and 5th of January 2026 to 19th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Abcellera Biologics price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Abcellera Biologics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.26 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Abcellera Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Abcellera Biologics reported net income of (162.86 Million). This is 147.72% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 128.52% higher than that of the company.
Abcellera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Abcellera Biologics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Abcellera Biologics could also be used in its relative valuation, which is a method of valuing Abcellera Biologics by comparing valuation metrics of similar companies.Abcellera Biologics is currently under evaluation in net income category among its peers.
Abcellera Biologics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Abcellera Biologics from analyzing Abcellera Biologics' financial statements. These drivers represent accounts that assess Abcellera Biologics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Abcellera Biologics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 3.9B | 2.9B | 1.7B | 862.4M | 991.7M | 942.1M | |
| Enterprise Value | 3.5B | 2.6B | 1.6B | 771.4M | 887.1M | 842.8M |
Abcellera Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Abcellera Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Abcellera Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Abcellera Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in Abcellera Biologics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Abcellera Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Abcellera Biologics' value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 3.3 M | Citadel Advisors Llc | 2025-06-30 | 2.9 M | Tang Capital Management Llc | 2025-06-30 | 2.6 M | Guardian Partners Inc. | 2025-06-30 | 1.8 M | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 996.9 K | Novo A/s | 2025-06-30 | 652.5 K | Norges Bank | 2025-06-30 | 630.9 K | State Street Corp | 2025-06-30 | 614.3 K | Susquehanna International Group, Llp | 2025-06-30 | 594.3 K | Baker Bros Advisors Lp | 2025-06-30 | 27.5 M | Capital World Investors | 2025-06-30 | 13.4 M |
Abcellera Fundamentals
| Return On Equity | -0.17 | ||||
| Return On Asset | -0.1 | ||||
| Operating Margin | (8.52) % | ||||
| Current Valuation | 574.48 M | ||||
| Shares Outstanding | 299.34 M | ||||
| Shares Owned By Insiders | 22.96 % | ||||
| Shares Owned By Institutions | 36.84 % | ||||
| Number Of Shares Shorted | 48.9 M | ||||
| Price To Earning | 16.67 X | ||||
| Price To Book | 0.97 X | ||||
| Price To Sales | 26.86 X | ||||
| Revenue | 28.83 M | ||||
| Gross Profit | (147.49 M) | ||||
| EBITDA | (204.15 M) | ||||
| Net Income | (162.86 M) | ||||
| Cash And Equivalents | 868.21 M | ||||
| Cash Per Share | 3.04 X | ||||
| Total Debt | 65.36 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 9.86 X | ||||
| Book Value Per Share | 3.22 X | ||||
| Cash Flow From Operations | (108.56 M) | ||||
| Short Ratio | 10.08 X | ||||
| Earnings Per Share | (0.57) X | ||||
| Price To Earnings To Growth | 2.22 X | ||||
| Target Price | 9.83 | ||||
| Number Of Employees | 596 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 948.89 M | ||||
| Total Asset | 1.36 B | ||||
| Retained Earnings | 116.93 M | ||||
| Working Capital | 674.76 M | ||||
| Net Asset | 1.36 B |
About Abcellera Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abcellera Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abcellera Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abcellera Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.459 | Earnings Share (0.57) | Revenue Per Share | Quarterly Revenue Growth 0.376 | Return On Assets |
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.